Imugene (Australia) Investor Sentiment

IMU Stock   0.04  0  2.56%   
Slightly above 61% of Imugene's investor base is looking to short. The analysis of the overall investor sentiment regarding Imugene suggests that many traders are alarmed. Imugene's investing sentiment can be driven by a variety of factors including economic data, Imugene's earnings reports, geopolitical events, and overall market trends.
  
over a week ago at news.google.com         
ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - MSN
Google News at Macroaxis
over a week ago at news.google.com         
Imugene Limited Announces Director Change and Stock Holdings - TipRanks
Google News at Macroaxis
over a month ago at news.google.com         
Imugene This exciting biotech has multiple clinical trial readouts expected in the next 12 months - ...
Google News at Macroaxis
over a month ago at news.google.com         
Imugene Ltd. announced that it has received AUD 2.60 million in funding. - Marketscreener.com
Google News at Macroaxis
over two months ago at news.google.com         
Just the Facts Imugene receives Orphan Drug Designation for VAXINIA from FDA - Proactive Investors U...
Google News at Macroaxis
over two months ago at news.google.com         
Precision BioSciences Receives 13 Million in Proceeds from Imugene Convertible Note Maturity as Part...
Google News at Macroaxis
over two months ago at news.google.com         
ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - Stockhead
Google News at Macroaxis
over three months ago at news.google.com         
Is Imugene In A Good Position To Invest In Growth - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
Imugene Shares Set for Escrow Release - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Imugene progresses clinical trials supported by strong cash runway By Proactive Investors - Investin...
Google News at Macroaxis
over three months ago at news.google.com         
The five-year returns have been splendid for Imugene shareholders despite underlying losses increasi...
Google News at Macroaxis
over three months ago at news.google.com         
Imugene Limited Announces Cessation of Securities - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Imugene Advances Cancer Treatment with onCARlytics Trial - TipRanks.com - TipRanks
Google News at Macroaxis
over three months ago at news.google.com         
Were Hopeful That Imugene Will Use Its Cash Wisely - Yahoo Canada Sports
Google News at Macroaxis
over three months ago at news.google.com         
Is Imugene In A Good Position To Deliver On Growth Plans - Yahoo Finance UK
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Imugene that are available to investors today. That information is available publicly through Imugene media outlets and privately through word of mouth or via Imugene internal channels. However, regardless of the origin, that massive amount of Imugene data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Imugene news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Imugene relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Imugene's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Imugene alpha.

Imugene Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Imugene Ltd. announced that it has received AUD 2.60 million in funding. - Marketscreener.com
10/04/2024
2
ASX Health Stocks Imugene reveals promise in lymphoma trial, stock soars 27pc - MSN
11/21/2024

Additional Tools for Imugene Stock Analysis

When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.